← All trials
NCT05292131
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 17, 2022
- Primary completion
- Jan 12, 2023
- Completion date
- Jan 12, 2023
- First posted
- Mar 23, 2022
- Last posted
- Sep 22, 2022
- Enrollment
- 121
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UCBLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.